Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
InVivo Therapeutics announces 1-for-30 reverse stock split » 16:30
02/03/20
02/03
16:30
02/03/20
16:30
NVIV

InVivo Therapeutics

$0.23 /

-0.0123 (-5.08%)

InVivo Therapeutics…

InVivo Therapeutics Holdings Corp. announced a 1-for-30 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on February 11, 2020, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the Company's existing trading symbol, "NVIV," at the market open on February 12, 2020. The new CUSIP number for the Company's common stock following the reverse stock split will be CUSIP 46186M 506/ISIN US46186M5067. At the effective time of the reverse stock split, every 30 shares of InVivo Therapeutics common stock will be combined into 1 share of InVivo Therapeutics common stock. In connection with the reverse stock split, the authorized shares will be reduced from 500 million shares to approximately 16.7 million shares. The reverse stock split is anticipated to reduce the company's issued and outstanding shares of common stock from approximately 17.8 million to approximately 0.6 million. Fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share, and all shares of common stock (including fractions thereof) issuable upon the reverse stock split to a given stockholder shall be aggregated for the purpose of determining whether the reverse stock split would result in the issuance of a fractional share. In addition, proportionate adjustments will be made to the exercise prices of the company's outstanding stock options and warrants and to the number of shares issued and issuable under the company's existing stock incentive plans. The implementation of the reverse stock split is intended to increase the per share trading price of the Company's common stock to fulfill the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Over a quarter ago
Syndicate
InVivo Therapeutics 7M share Spot Secondary priced at $0.12 » 08:46
11/21/19
11/21
08:46
11/21/19
08:46
NVIV

InVivo Therapeutics

$0.27 /

-0.0195 (-6.67%)

H.C. Wainwright is acting…

H.C. Wainwright is acting as sole book running manager for the offering.

Syndicate
InVivo Therapeutics files to sell common stock, no amount given » 08:17
11/18/19
11/18
08:17
11/18/19
08:17
NVIV

InVivo Therapeutics

$0.43 /

+0.0103 (+2.43%)

H.C. Wainwright & Co.…

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

Syndicate
InVivo Therapeutics files $20M mixed securities shelf  16:35
10/28/19
10/28
16:35
10/28/19
16:35
NVIV

InVivo Therapeutics

$0.44 /

+ (+0.00%)

 
Hot Stocks
InVivo Therapeutics announces INSPIRE 2.0 study at 25% enrollment » 08:04
10/22/19
10/22
08:04
10/22/19
08:04
NVIV

InVivo Therapeutics

$0.49 /

+0.03 (+6.52%)

InVivo Therapeutics…

InVivo Therapeutics announced that a total of five patients have been enrolled into the INSPIRE 2.0 Study, bringing the study to 25% completion of targeted enrollment. The first patient was enrolled into the INSPIRE 2.0 Study in May and 14 sites are currently open for enrollment into the study.

Hot Stocks
InVivo Therapeutics enrolls first 2 patients into INSPIRE 2.0 study » 08:06
05/29/19
05/29
08:06
05/29/19
08:06
NVIV

InVivo Therapeutics

$1.17 /

+0.04 (+3.54%)

InVivo Therapeutics…

InVivo Therapeutics announced that the first two patients have been enrolled into The INSPIRE 2.0 Study, or InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The INSPIRE 2.0 Study is a two-arm 20-patient--10 subjects in each study arm--randomized, controlled trial designed to provide clinical data that will supplement the existing clinical results from the company's previous single-arm study. The definition of study success for the INSPIRE 2.0 Study is that the difference in the proportion of subjects who demonstrate an improvement of at least one grade on ASIA Impairment Scale assessment at the six-month primary endpoint follow-up visit between the Scaffold Arm and the Comparator Arm must be equal to or greater than 20%.

ShowHide Related Items >><<
Hot Stocks
InVivo Therapeutics announces presentation of twelve-month INSPIRE study results » 08:04
04/17/19
04/17
08:04
04/17/19
08:04
NVIV

InVivo Therapeutics

$1.55 /

-0.02 (-1.27%)

InVivo Therapeutics…

InVivo Therapeutics Holdings announced the presentation of the twelve-month results from the company's single-arm INSPIRE study. The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, "Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold(TM) in Acute Thoracic Complete Spinal Cord Injury". As previously announced by InVivo, 7 of 16 patients who reached the six-month primary endpoint visit in the INSPIRE study had an ASIA Impairment Scale conversion at 6 months, which is the primary endpoint of the trial. Of the seven patients who reached the six-month primary endpoint visit, six patients were later evaluated at the 12-month exam and one patient was lost to follow-up before the 12-month exam. All six patients who were examined at the 12-month exam and had previously converted at the six-month exam remained converted at the 12-month exam. Further, two of those six patients were assessed to have AIS B spinal cord injury at the six-month primary endpoint but were later assessed to have improved to AIS C SCI at the 12-month visit. The Objective Performance Criterion for the study was a 25% AIS conversion rate based on the published conversion rates for thoracic SCI reported in the literature.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.